Cargando…

Bone Marrow Aplasia after CAR-T-Cell Therapy for Relapsed/Refractory Burkitt’s Lymphoma

Chimeric antigen receptor T-cells (CAR-T) are now a standard approach for treating relapsed/refractory B-cell lymphomas. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) is a newly described entity that can manifest following CAR-T. Bone marrow (BM) aplasia i...

Descripción completa

Detalles Bibliográficos
Autores principales: Kenkel, Troy J., Sridhar, Nithya, Hammons, Lindsay R., Hintzke, Maria, Shah, Nirav N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594436/
https://www.ncbi.nlm.nih.gov/pubmed/37873752
http://dx.doi.org/10.3390/medsci11040067
_version_ 1785124649407873024
author Kenkel, Troy J.
Sridhar, Nithya
Hammons, Lindsay R.
Hintzke, Maria
Shah, Nirav N.
author_facet Kenkel, Troy J.
Sridhar, Nithya
Hammons, Lindsay R.
Hintzke, Maria
Shah, Nirav N.
author_sort Kenkel, Troy J.
collection PubMed
description Chimeric antigen receptor T-cells (CAR-T) are now a standard approach for treating relapsed/refractory B-cell lymphomas. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) is a newly described entity that can manifest following CAR-T. Bone marrow (BM) aplasia is an uncommon manifestation of IEC-HS reported after CAR-T-cell therapy and is defined as the reduction or absence of hematopoietic progenitor cells resulting in severe pancytopenia. We describe the case of a 44-year-old female with relapsed/refractory Burkitt lymphoma (BL) who received treatment with lisocabtagene maraleucel with her post-CAR-T course complicated by cytokine release syndrome (CRS) and IEC-HS ultimately leading to persistent BM aplasia. She underwent a rescue allogeneic stem cell transplant but ultimately succumbed to progressive disease. IEC-HS is an increasingly recognized complication that occurs after CAR-T treatments that can result in aplasia, a dangerous complication with serious sequelae including infection, transfusion dependence, and high risk for hemorrhage. The underlying mechanism is poorly understood, and further studies are needed to understand how to treat it better.
format Online
Article
Text
id pubmed-10594436
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105944362023-10-25 Bone Marrow Aplasia after CAR-T-Cell Therapy for Relapsed/Refractory Burkitt’s Lymphoma Kenkel, Troy J. Sridhar, Nithya Hammons, Lindsay R. Hintzke, Maria Shah, Nirav N. Med Sci (Basel) Case Report Chimeric antigen receptor T-cells (CAR-T) are now a standard approach for treating relapsed/refractory B-cell lymphomas. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) is a newly described entity that can manifest following CAR-T. Bone marrow (BM) aplasia is an uncommon manifestation of IEC-HS reported after CAR-T-cell therapy and is defined as the reduction or absence of hematopoietic progenitor cells resulting in severe pancytopenia. We describe the case of a 44-year-old female with relapsed/refractory Burkitt lymphoma (BL) who received treatment with lisocabtagene maraleucel with her post-CAR-T course complicated by cytokine release syndrome (CRS) and IEC-HS ultimately leading to persistent BM aplasia. She underwent a rescue allogeneic stem cell transplant but ultimately succumbed to progressive disease. IEC-HS is an increasingly recognized complication that occurs after CAR-T treatments that can result in aplasia, a dangerous complication with serious sequelae including infection, transfusion dependence, and high risk for hemorrhage. The underlying mechanism is poorly understood, and further studies are needed to understand how to treat it better. MDPI 2023-10-12 /pmc/articles/PMC10594436/ /pubmed/37873752 http://dx.doi.org/10.3390/medsci11040067 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Kenkel, Troy J.
Sridhar, Nithya
Hammons, Lindsay R.
Hintzke, Maria
Shah, Nirav N.
Bone Marrow Aplasia after CAR-T-Cell Therapy for Relapsed/Refractory Burkitt’s Lymphoma
title Bone Marrow Aplasia after CAR-T-Cell Therapy for Relapsed/Refractory Burkitt’s Lymphoma
title_full Bone Marrow Aplasia after CAR-T-Cell Therapy for Relapsed/Refractory Burkitt’s Lymphoma
title_fullStr Bone Marrow Aplasia after CAR-T-Cell Therapy for Relapsed/Refractory Burkitt’s Lymphoma
title_full_unstemmed Bone Marrow Aplasia after CAR-T-Cell Therapy for Relapsed/Refractory Burkitt’s Lymphoma
title_short Bone Marrow Aplasia after CAR-T-Cell Therapy for Relapsed/Refractory Burkitt’s Lymphoma
title_sort bone marrow aplasia after car-t-cell therapy for relapsed/refractory burkitt’s lymphoma
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594436/
https://www.ncbi.nlm.nih.gov/pubmed/37873752
http://dx.doi.org/10.3390/medsci11040067
work_keys_str_mv AT kenkeltroyj bonemarrowaplasiaaftercartcelltherapyforrelapsedrefractoryburkittslymphoma
AT sridharnithya bonemarrowaplasiaaftercartcelltherapyforrelapsedrefractoryburkittslymphoma
AT hammonslindsayr bonemarrowaplasiaaftercartcelltherapyforrelapsedrefractoryburkittslymphoma
AT hintzkemaria bonemarrowaplasiaaftercartcelltherapyforrelapsedrefractoryburkittslymphoma
AT shahniravn bonemarrowaplasiaaftercartcelltherapyforrelapsedrefractoryburkittslymphoma